medigraphic.com
ISSN 1527-3172 (Electronic)

2021, Number 1

<< Back Next >>

MEDICC Review 2021; 23 (1)

Non-Alcoholic Fatty Liver Disease in Cuba

Castellanos-Fernández MI, Crespo-Ramírez E, del Valle-Díaz S, Barreto-Suárez E, Díaz-Elías JO, Santaló-Rodríguez L, Corrales-Alonso S, Morales-Martínez I, Cedeño-Ramírez E, Pérez-González T, González-Suero SM, Ruenes-Domech C, Infante-Velázquez M, Borges-González SÁ, Elvírez-Gutiérrez A, Lazo-del Vallín S, Villa-Jiménez OM, Labrada-Moreno LM

Language: English
References: 54
Page: 64-71
PDF size: 162.74 Kb.


ABSTRACT

INTRODUCTION With a global adult prevalence of 24%, nonalcoholic fatty liver disease is a global health problem that parallels the worldwide increase of obesity. Its frequency, clinical characteristics and related diseases in Cuba remain unknown.
OBJECTIVE Describe the clinical characteristics, comorbidities and personal habits of patients with non-alcoholic fatty liver disease who are being treated in secondary and tertiary health facilities in seven Cuban provinces.
METHODS A cross-sectional, multicenter study was carried out in 6601 adults seen at gastroenterology outpatient clinics of nine hospitals in seven Cuban provinces from September 2018 through May 2019. Non-alcoholic fatty liver disease was diagnosed by abdominal ultrasound. The study included 1070 patients who met the diagnostic and study criteria and agreed to participate. Their personal habits and anthropometric and clinical characteristics, comorbidities and other aspects of their medical histories were recorded.
RESULTS Of the 1070 participants, 60.7% (649) were women. Participants’ average age was 54.5 years and average body mass index was 30.5 kg/m2. A total of 397 (37.1%) were overweight and 574 (53.6%) were obese, 945 (88.3%) led a sedentary lifestyle, 564 (52.7%) had high blood pressure, 406 (37.9%) had lipid disorders and 301 (28.1%) were diabetic. While 484 (45.2%) of patients were asymptomatic, the most frequent clinical signs and symptoms were fatigue (262; 24.5%), dyspepsia (209; 19.5%), abdominal pain (306; 28.5%) and hepatomegaly (189; 17.7%). Liver cirrhosis was present in 37 (3.5%) patients at the time of diagnosis. Family history of type 2 diabetes mellitus and obesity were identifi ed in 391 (36.5%) and 279 (26.1%) of participants, respectively.
CONCLUSIONS Prevalence of non-alcoholic fatty liver disease in these Cuban patients coincides with that reported in the Caribbean region, which has high levels of obesity, overweight and sedentary lifestyles. Most were asymptomatic, female or had metabolism-related comorbidities such as high blood pressure, type 2 diabetes mellitus and dyslipidemia.


REFERENCES

  1. Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology [Internet]. 2018 Jan [cited 2019 Feb 19];67(1):328–57. Available at: https://doi.org/10.1002/hep.29367

  2. European Association for the Study of the Liver (EASL); European Association for the Study of Obesity Diabetes (EASO). EASL-EASDEASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Obes Facts [Internet]. 2016 May [cited 2020 Feb 19];9(2):65–90. Available at: https://doi .org/10.1159/000443344

  3. Patel V, Sanyal AJ, Sterling R. Clinical presentation and patient evaluation in nonalcoholic fatty liver disease. Clin Liver Dis. 2016 May;20(2):277–92.

  4. Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: The State of the Disease. Gastroenterology. 2020 May;158(7):1851–64.

  5. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology [Internet]. 2016 Jul [cited 2020 Aug 26];64(1):73–84. Available at: https:// doi.org/10.1002/hep.28431

  6. Paul S, Davis AM. Diagnosis and management of nonalcoholic fatty liver disease. JAMA. 2018 Dec 18;320(23):2474–5.

  7. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013 Nov;10(11):686–90.

  8. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol [Internet]. 2018 Jan;15(1):11–20. Available at: http:// dx.doi.org/10.1038/nrgastro.2017.109

  9. World Health Organization [Internet]. Geneva: World Health Organization; c2020. Centro de prensa. Notas descriptivas. Obesidad y sobrepeso; 2020 [updated 2020 Apr 1; cited 2020 Jun10]. Available at: https://www.who.int/es/news-room/ fact-sheets/detail/obesity-and-overweight. Spanish.

  10. World Health Organization [Internet]. Geneva: World Health Organization; c2020. Global Health Observatory (GHO). Reports. World health statistics 2016: monitoring health for the SDGs sustainable development goals. World Health Organization; 2016 [cited 2020 Feb 15]. Available at: https://www.who.int/gho/publications/ world_health_statistics/2016/en/

  11. López-Velázquez JA, Silva-Vidal KV, Ponciano- Rodríguez G, Chávez-Tapia NC, Arrese M, Uribe M, et al. The prevalence of nonalcoholic fatty liver disease in the Americas. Ann Hepatol. 2014 Mar– Apr;13(2):166–78.

  12. de Oliveira CPMS, Cotrim HP, Arrese M. Factores de riesgo de la enfermedad por hígado graso no alcohólico en poblaciones de Latinoamérica: situación actual y perspectivas. Clin Liver Dis (Hoboken). 2019 May 29;13(Suppl 1):S5–S8. Spanish.

  13. Loomba R, Abraham M, Unalp A, Wilson L, Lavine J, Doo E, et al. Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fi brosis. Hepatology. 2012 Sep;56(3):943–51.

  14. Jiménez Acosta SM, Magaly S, Rodríguez Suárez A, Díaz Sánchez ME. La obesidad en Cuba. Una mirada a su evolución en diferentes grupos poblacionales. Rev Cubana Alimen Nutr. 2013;23(2):297–308. Spanish. Available at: http://www.revalnutricion .sld.cu/index.php/rcan/article/view/299

  15. National Health Statistics and Medical Records Division (CU). Anuario Estadístico de Salud 2019 [Internet]. Havana: Ministry of Public Health (CU); 2020 Apr [cited 2020 Jun 15]. 193 p. Available at: https://fi les.sld.cu/bvscuba/fi les/2020/05/Anua rio-Electr%c3%b3nico-Espa%c3%b1ol-2019 -ed-2020.pdf. Spanish.

  16. National Health Statistics and Medical Records Division (CU). Anuario Estadístico de Salud 2010. Havana: Ministry of Public Health (CU); 2011 Apr [cited 2020 Jun 15]. 199 p. Available at: https://fi les.sld.cu/dne/fi les/2011/04/anuario -2010-e-sin-grafi cos1.pdf. Spanish.

  17. Montero González T, Pérez Lorenzo M, Alarcón Arango I, Infante Velázquez M, Angulo Pérez O, Winogra Lay R, et al. Prevalencia de esteatosis hepática no alcohólica en autopsias y alteraciones morfológicas metabólicas relacionadas. Rev Cub Med Mil. 2011;40(1):32–9. Spanish.

  18. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA [Internet]. 2001 May 16 [cited 2020 Feb 15];285(19):2486–97. Available at: https://jamanetwork.com/journals/jama/fullarti cle/vol/285/pg/2486

  19. Díaz Sánchez ME. Manual de técnicas antropométricas para estudios nutricionales. Havana: Nutrition and Food Hygiene Institute (CU); 2005. Spanish.

  20. World Health Organization [Internet]. Geneva: World Health Organization; c2020. Estrategia mundial sobre régimen alimentario, actividad física y salud. ¿Qué se entiende por actividad moderada y actividad vigorosa?; 2019 [cited 2019 Dec 25]. Available at: https://www.who.int/ dietphysicalactivity/physical_activity_intensity/ es/. Spanish.

  21. National Institute on Alcohol Abuse and Alcoholism (US). Helping Patients who Drink Too Much: A Clinician’s Guide: Updated 2005 Edition [Internet]. Maryland: National Institutes of Health (US); 2005 [revised 2016 Jul; cited 2019 Dec 20]. 34 p. Available at: https://pubs.niaaa.nih.gov/publica tions/practitioner/cliniciansguide2005/guide.pdf

  22. Reboussin DM, Allen NB, Griswold ME, Guallar E, Hong Y, Lackland DT, et al. Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension. 2018 Jun;71(6):e116–e35.

  23. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39(33):3021–104.

  24. World Medical Association. World Medical Associatioin Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013 Nov 27;310(20):2191–4.

  25. van Delden JJ, van der Graaf R. Revised CIOMS International Ethical Guidelines for Health-Related Research Involving Humans. JAMA. 2017 Jan;317(2):135–6.

  26. Fernández MTC, Duharte JF, Maren DM, Botiel LBB, Diarra O. Hallazgos clínicos e histomorfológicos en pacientes con esteatosis hepática no alcohólica. MediSan. 2014;18(8):1173–9. Spanish.

  27. Fondén JD, Pereira Despaigne OL, Columbié AL, Del Valle Díaz S, Hodelín Tablada R. Relación entre los hallazgos ecográfi cos, laparoscópicos e histológicos en pacientes con esteatosis hepática no alcohólica. MediSan. 2015;19(03):345– 53. Spanish.

  28. Canciano Chirino E, Iglesia Reyes CK, de Armas Romero I, Fandiño González L, Iglesia Reyes ME, Río Ponciano O. Hígado graso no alcohólico como marcador de calidad de vida en mujeres de edad mediana. Rev Cubana Obstetr Ginecol. 2011;37(4):533–40. Spanish.

  29. Creagh García J, Suárez Sori B, Hernández Rodríguez M, Martínez Paradela T. Resultados de la biopsia hepática en el diagnóstico del hígado graso no alcohólico. Rev Arch Médico Camagüey. 2017 Jul–Aug;21(4):518–27. Spanish.

  30. del Busto Mesa A, Cabrera Rego JO, Guanche Valenciano O. Cintura hipertrigliceridémica y enfermedad por hígado graso no alcohólico en pacientes hipertensos. Rev Cubana Med. 2017 Jan–Mar;56(1):4–14. Spanish.

  31. Fleischman MW, Budoff M, Zeb I, Li D, Foster T. NAFLD prevalence differs among hispanic subgroups: the Multi-Ethnic Study of Atherosclerosis. World J Gastroenterol. 2014 May 7;20(17):4987–93.

  32. Matteoni L, Boente L, Soares D, Leal R, Campos F, César Araújo, et al. [Nonalcoholic fatty hepatic disease: relevance of the diagnosis on abdominal ultrasound]. Gaz Méd Bahia. 2011 Jan–Jun;81(1):7–9. Portuguese.

  33. Karnikowski M, Córdova C, d’Oliveira RJ, d’Oliveira Karnikowski MG, de Toledo Nóbrega O. Non-alcoholic fatty liver disease and metabolic syndrome in Brazilian middle-aged and older adults. Sao Paulo Med J. 2007 Nov 1;125(6):333–7.

  34. Parise ER, Salgado ALFDA, Secaf R, Cerri LMO, Cerri G. Prevalence of liver steatosis in abdominal ultrasound. GED. 2003 Nov;22(6):235–7.

  35. Riquelme A, Arrese M, Soza A, Morales A, Baudrand R, Pérez-Ayuso RM, et al. Non-alcoholic fatty liver disease and its association with obesity, insulin resistance and increased serum levels of C-reactive protein in Hispanics. Liver Int. 2009 Jan;29(1):82–8.

  36. Pérez M, Gonzáles L, Olarte R, Rodríguez NI, Tabares M, Salazar JP, et al. Nonalcoholic fatty liver disease is associated with insulin resistance in a young Hispanic population. Prev Med. 2011 Feb;52(2):174–7.

  37. Bonet Gorbea M, Varona P, Chang de la Rosa M, García Roche R, Suárez Medina R, Arcia N, et al. III Encuesta Nacional de Factores de Riesgo y Actividades Preventivas de Enfermedades No Transmisibles. Cuba 2010-2011 [Internet]. Havana: ECIMED; 2014 Aug 23 [cited 2015 Jun17]. Available at: https://www.researchgate .net/publication/325370475_III_Encuesta _Nacional_de_factores_de_riesgo_y_activi dades_preventivas_de_enfermedades_no _trasmisibles_Cuba_2010-2011. Spanish.

  38. Jiménez Acosta S, Díaz Sánchez ME, García Roche RG, Bonet Gorbea M, Wong Ordóñez I. Cambios en el estado nutricional de la población cubana adulta de diferentes regiones de Cuba. Rev Cubana Hig Epidemiol [Internet]. 2012 Jan– Apr [cited 2020 May 22];50:4–13. Available at: http://scielo.sld.cu/scielo.php?script=sci_arttext &pid=S1561-30032012000100002. Spanish.

  39. Akhavan Rezayat A, Dadgar Moghadam M, Ghasemi Nour M, Shirazinia M, Ghodsi H, Rouhbakhsh Zahmatkesh MR, et al. Association between smoking and nonalcoholic fatty liver disease: a systematic review and meta-analysis. SAGE Open Med. 2018 Jan 24;6:2050312117745223. DOI: 10.1177/2050312117745223.

  40. Guthold R, Stevens GA, Riley LM, Bull FC. Worldwide trends in insuffi cient physical activity from 2001 to 2016: a pooled analysis of 358 population-based surveys with 1.9 million participants. Lancet Global Health. 2018 Oct;6(10):e1077–e86.

  41. Fattahi MR, Niknam R, Safarpour A, Sepehrimanesh M, Lotfi M. The prevalence of metabolic syndrome in non-alcoholic fatty liver disease: a population-based study. Middle East J Digest Dis [Internet]. 2016 Apr [cited 2020 Mar 14];8(2):131–7. Available at: https://www.ncbi .nlm.nih.gov/pmc/articles/pmid/27252820/

  42. Povsic M, Wong OY, Perry R, Bottomley J. A structured literature review of the epidemiology and disease burden of non-alcoholic steatohepatitis (NASH). Adv Ther [Internet]. 2019 Jul [cited 2020 Aug 18];36(7):1574–94. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/ pmid/31065991/

  43. Lonardo A, Nascimbeni F, Ballestri S, Fairweather D, Win S, Than TA, et al. Sex differences in nonalcoholic fatty liver disease: state of the art and identifi cation of research gaps. Hepatology. 2019 Oct;70(4):1457–69.

  44. Du T, Sun X, Yuan G, Zhou X, Lu H, Lin X, et al. Sex differences in the impact of nonalcoholic fatty liver disease on cardiovascular risk factors. Nutr Metab Cardiovasc Dis. 2017 Jan;27(1):63–9.

  45. Ye ZL, Guo WQ, Li L. Sex-based differences in the association between nonalcoholic fatty liver disease and mortality. Clin Gastroenterol Hepatol. 2019 Jan;17(1):211–2.

  46. McCracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome. Clin Dermatol [Internet]. 2018 Jan–Feb [cited 2020 Apr 18];36(1):14–20. Available at: https:// linkinghub.elsevier.com/retrieve/pii/S0738 -081X(17)30158-X

  47. Younossi ZM, Stepanova M, Negro F, Hallaji S, Younossi Y, Lam B, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine (Baltimore) [Internet]. 2012 Nov [cited 2020 Apr 18];91(6):319– 27. Available at: https://doi.org/10.1097/ MD.0b013e3182779d49

  48. Sookoian S, Pirola CJ. Genetic predisposition in nonalcoholic fatty liver disease. Clin Molecular Hepatol. 2017 Mar;23(1):1–12.

  49. Eslam M, Valenti L, Romeo S. Genetics and epigenetics of NAFLD and NASH: Clinical impact. J Hepatol. 2018 Feb;68(2):268–79.

  50. Shen J, Wong GLH, Chan HL, Chan HLY, Yeung DKW, Chan RSM, et al. PNPLA3 gene polymorphism accounts for fatty liver in community subjects without metabolic syndrome. Aliment Pharmacol Ther [Internet]. 2014 Mar [cited 2020 Apr 18];39(5):532–9. Available at: https://doi .org/10.1111/apt.12609

  51. Cintado A, Companioni O, Nazabal M, Camacho H, Ferrer A, Fernández De Cossio ME, et al. Admixture estimates for the population of Havana City. Ann Human Biol [Internet]. 2009 May–Jun [cited 2020 Apr 20];36(3):350–60. Available at: http://www.tandfonline.com/doi/ full/10.1080/03014460902817984

  52. Marcheco-Teruel B, Parra EJ, Fuentes-Smith E, Salas A, Buttenschøn HN, Demontis D, et al. Cuba: exploring the history of admixture and the genetic basis of pigmentation using autosomal and uniparental markers. PLoS Genet. 2014 Jul 24;10(7):e1004488.

  53. Caldwell SH, Cr espo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol [Internet]. 2004 Apr [cited 2020 Apr 20];40(4):578–84. Available at: https://linkinghub.elsevier.com/retrieve/pii/ S0168827804000716

  54. Vilar-Gómez E, Calzadilla-Bertot L, Wong VWS, Castellanos M, Aller-de la Fuente R, Metwally M, et al. Fibrosis severity as a determinant of cause-specifi c mortality in patients with advanced nonalcoholic fatty liver disease: a multi-national cohort study. Gastroenterology [Internet]. 2018 Aug [cited 2020 Apr 21];155(2):443–57. Available at: https:// linkinghub.elsevier.com/retrieve/pii/S0016 -5085(18)34484-6




2020     |     www.medigraphic.com